Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Cancer survivor Zoe Plastiras hopes her message provides some reassurance by highlighting advances in cancer treatment.

Dan Evans, 19, from Newark in Nottinghamshire, described his huge relief ringing the "cancer-free bell" at the teenage cancer ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete response Across clinical trials, Breyanzi has ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

A 19-year-old is celebrating being cancer-free – a year after he was told that there was no hope and to “go home and make memories with his family”.

Brandow, who learned she had stage 4 lymphoma in 2020 after giving birth to her younger son, wants to lift barriers to health ...

Kite Pharma provides products like Chimeric Antigen Receptors(CAR), KTE-C19 DLBCL, PMBCL, TFL (ZUMA-1); Chemo Refractory Diffuse Large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma ...

Maplirpacept is under clinical development by Pfizer and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase II drugs for Primary Mediastinal B-Cell Lymphoma ...

An emotional two-year journey reached a heart-warming milestone as Newark’s miracle boy, who defied all the odds to ring his ...